Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mytrex Health TechnologiesROCO:4431 -0.50%71 Debt-to-EBITDA is 2.47 as of Jun. 2026, which is 38% above its 10-year median of 1.79. GuruFocus rates ROCO:4431 with a GF Score™ of 71/100 and a GF Value™ of NT$28.79 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 2,308 Industrial Products companies, Mytrex Health Technologies ranks worse than 63.95% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Mytrex Health Technologies's Debt-to-EBITDA or its related term are showing as below:
ROCO:4431'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.37 Med: 1.79 Max: 13.09
Current: 2.77
During the past 13 years, the highest Debt-to-EBITDA Ratio of Mytrex Health Technologies was 13.09. The lowest was 0.37. And the median was 1.79.
ROCO:4431's Debt-to-EBITDA is ranked worse than 63.95% of 2308
companies
in the Industrial Products industry
Industry Median: 1.69
vs ROCO:4431: 2.77
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Mytrex Health Technologies Debt-to-EBITDA Related Terms
Mytrex Health Technologies Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4431 vs GEV, ETN, PH: Debt-to-EBITDA Comparison
For the Specialty Industrial Machinery subindustry, Mytrex Health Technologies's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mytrex Health Technologies Debt-to-EBITDA vs Industrial Products Industry
For the Industrial Products industry and Industrials sector, Mytrex Health Technologies's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Mytrex Health Technologies's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Jun. 2026) EBITDA data.
Mytrex Health Technologies (ROCO:4431) has a Debt-to-EBITDA of 2.47 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Mytrex Health Technologies. This is 38% above median its historical median of 1.79. Over the past decade, Mytrex Health Technologies' Debt-to-EBITDA has ranged from 0.37 to 13.09. According to the industry distribution chart, Mytrex Health Technologies ranks #1476 out of 2308 companies in the Industrial Products industry, placing it in the top 64%.
Is Mytrex Health Technologies' Debt-to-EBITDA too high?
Mytrex Health Technologies' current Debt-to-EBITDA of 2.47 is 38% above median its 10-year median of 1.79. Over the past 10 years, this metric has ranged from a low of 0.37 to a high of 13.09. The Industrial Products industry median Debt-to-EBITDA is 1.69. Mytrex Health Technologies' value of 2.47 is 46.2% above this industry median. Based on the distribution chart, Mytrex Health Technologies ranks #1476 out of 2308 companies in the Industrial Products industry, which is below the industry midpoint. Overall, Mytrex Health Technologies has a GF Score™ of 71/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Mytrex Health Technologies' Debt-to-EBITDA compare to GEV and ETN?
According to the Industrial Products industry distribution chart, Mytrex Health Technologies ranks #1476 out of 2308 companies for Debt-to-EBITDA. This places Mytrex Health Technologies in the lower half of its industry. The industry median Debt-to-EBITDA is 1.69. Mytrex Health Technologies' value of 2.47 is 46.2% above this benchmark. Historically, Mytrex Health Technologies' own Debt-to-EBITDA has ranged from 0.37 to 13.09 over the past decade. While the company's 10-year median is 1.79 vs. the industry median of 1.69, Mytrex Health Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for an Industrial Products company?
The median Debt-to-EBITDA among Industrial Products companies is 1.69, based on 2,308 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mytrex Health Technologies's current Debt-to-EBITDA of 2.47 is 46.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Mytrex Health Technologies. For the Industrial Products industry, the median Debt-to-EBITDA is 1.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mytrex Health Technologies's current Debt-to-EBITDA is 2.47, which is 38% above median its own 10-year median of 1.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mytrex Health Technologies stock overvalued right now?
Based on GuruFocus' analysis, Mytrex Health Technologies (ROCO:4431) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$28.79, compared to a current price of NT$20.00 — trading 30.5% below its estimated fair value. The current Debt-to-EBITDA is 2.47, which is 38% above median its 10-year median of 1.79 and 46.2% above the Industrial Products industry median of 1.69. Mytrex Health Technologies' overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Mytrex Health Technologies (ROCO:4431), the current Debt-to-EBITDA is 2.47 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mytrex Health Technologies (ROCO:4431) Overvalued in 2026?
Based on GuruFocus' analysis, Mytrex Health Technologies stock appears to be undervalued.
The current stock price of NT$20.00 is trading 30.5% below its estimated GF Value™ of NT$28.79.
GuruFocus considers Mytrex Health Technologies to be Significantly Undervalued.
Key valuation signals for ROCO:4431:
Debt-to-EBITDA: 2.47 (38% above median its 10-year median of 1.79)
GF Value™: NT$28.79 vs. price of NT$20.00 (30.5% below fair value)
Industry Position: 46.2% above the Industrial Products median (#1476 of 2308)
No single metric tells the full story. See the ROCO:4431 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mytrex Health Technologies Inc is a Taiwan-based company engaged in the manufacturing of non-woven materials and special medical supplies. It is engaged in the development and production of melt-blown products for the protection of the environment and human health. The company offers products ranging from medical to industrial filtration materials such as various types of filtration media, lab coats or outfits, cabin filtration, vacuum cleaner filter bags, and special medical supplies. Its product categories include meltdown, mammoth bedding, and specialized medical supplies like balloon catheters and coronary stents.
71GF Score
Get the complete analysis for ROCO:4431
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4431 has been successfully added to your 
